

Giusy Elia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5879561/publications.pdf>

Version: 2024-02-01

59
papers

2,007
citations

304743

22
h-index

276875

41
g-index

59
all docs

59
docs citations

59
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	Hashimoto's™ thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101367.	4.7	251
2	The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. Autoimmunity Reviews, 2016, 15, 1125-1128.	5.8	155
3	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4413.	4.1	140
4	Graves'™ disease: Epidemiology, genetic and environmental risk factors and viruses. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101387.	4.7	120
5	Thyroid autoimmune disorders and cancer. Seminars in Cancer Biology, 2020, 64, 135-146.	9.6	100
6	The association of other autoimmune diseases in patients with Graves' disease (with or without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 287-292.	5.8	91
7	Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients'™ subgroups. Journal of Autoimmunity, 2021, 125, 102744.	6.5	83
8	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
9	Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101388.	4.7	72
10	Novel treatments for anaplastic thyroid carcinoma. Gland Surgery, 2020, 9, S28-S42.	1.1	69
11	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology, 2022, 79, 180-196.	9.6	64
12	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	4.7	60
13	Th1 Chemokines in Autoimmune Endocrine Disorders. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1046-1060.	3.6	56
14	Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surgery, 2018, 7, S19-S29.	1.1	44
15	Endocrine disruptors and thyroid autoimmunity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101377.	4.7	43
16	Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncology Reports, 2018, 39, 2225-2234.	2.6	38
17	Systemic Lupus Erythematosus and Thyroid Autoimmunity. Frontiers in Endocrinology, 2017, 8, 138.	3.5	34
18	Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. Immunologic Research, 2017, 65, 681-686.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Myo-inositol in autoimmune thyroiditis, and hypothyroidism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 349-354.	5.7	28
20	Novel therapies for thyroid autoimmune diseases: An update. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101366.	4.7	26
21	Novel Therapies for Thyroid Autoimmune Diseases. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 853-861.	3.1	25
22	Chemokines in hyperthyroidism. <i>Journal of Clinical and Translational Endocrinology</i> , 2019, 16, 100196.	1.4	25
23	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	3.9	25
24	Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?. <i>Journal of Immunology Research</i> , 2019, 2019, 1-11.	2.2	24
25	Cytokines as Targets of Novel Therapies for Gravesâ€™ Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 654473.	3.5	24
26	Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. <i>Oncology Reports</i> , 2018, 39, 2306-2314.	2.6	21
27	THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. <i>European Journal of Endocrinology</i> , 2021, 184, R29-R40.	3.7	20
28	Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. <i>Frontiers in Endocrinology</i> , 2018, 9, 764.	3.5	19
29	Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. <i>Nutrients</i> , 2020, 12, 1337.	4.1	19
30	The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101372.	4.7	16
31	<p>Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7893-7907.	1.9	14
32	CCL2 is Modulated by Cytokines and PPAR-Î³ in Anaplastic Thyroid Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 458-466.	1.7	14
33	Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. <i>Autoimmunity Reviews</i> , 2016, 15, 747-751.	5.8	13
34	Novel treatment options for anaplastic thyroid cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 279-288.	2.4	13
35	L-T4 Therapy in Enteric Malabsorptive Disorders. <i>Frontiers in Endocrinology</i> , 2021, 12, 626371.	3.5	13
36	Precision Medicine in Gravesâ€™ Disease and Ophthalmopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 754386.	3.5	13

#	ARTICLE	IF	CITATIONS
37	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. <i>Seminars in Cancer Biology</i> , 2022, 79, 203-216.	9.6	12
38	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	1.9	12
39	The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results. <i>Immunologic Research</i> , 2018, 66, 710-722.	2.9	11
40	The protective effect of myo-inositol on human thyrocytes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 355-362.	5.7	11
41	Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism. <i>Frontiers in Pharmacology</i> , 2021, 12, 750380.	3.5	11
42	The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine. <i>Frontiers in Endocrinology</i> , 2021, 12, 633587.	3.5	10
43	Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e675-e676.	3.9	10
44	Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102866.	6.5	10
45	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5731.	4.1	9
46	Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. <i>Gland Surgery</i> , 2019, 8, 298-300.	1.1	8
47	The Covid-19, Epidemiology, Clinic and Prevention. <i>Current Genomics</i> , 2020, 21, 157-160.	1.6	7
48	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
49	Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells. <i>Molecular Medicine Reports</i> , 2018, 17, 7415-7420.	2.4	5
50	Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 599-610.	1.8	5
51	Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 37-49.	0.7	3
52	Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 913-921.	4.1	3
53	Oral Liquid L-Thyroxine (L-T4) May Be Better Absorbed in Comparison to L-T4 Tablets in Patients With Lactose Intolerance. <i>Journal of the Endocrine Society</i> , 2021, 5, A832-A832.	0.2	1
54	The Synergistic Effect of Corticosteroids and Mycophenolic Acid on Chemokines in Orbital Cells From Patients With Graves'™ Ophthalmopathy. <i>Journal of the Endocrine Society</i> , 2021, 5, A845-A846.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Serum TSH Levels Normalisation in Patients Affected by Autoimmune Atrophic Gastritis, After the Switch From Oral L-T4 in Tablet Form to L-T4 in Liquid Formulation. Journal of the Endocrine Society, 2021, 5, A833-A833.	0.2	0
56	MON-566 Early Diagnosis of Lymph Node Metastases by Serum Tg and Neck Ultrasonography, and Long Term Follow Up After Radioiodine and/or Surgical Treatment in Patients with Papillary or Follicular Thyroid Cancer.. Journal of the Endocrine Society, 2019, 3, .	0.2	0
57	MON-594 Report Of A Large Series Of Patients With Graves' Disease (with/without Graves') Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Diseases. Journal of the Endocrine Society, 2019, 3, .	0.2	0
58	MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation. Journal of the Endocrine Society, 2019, 3, .	0.2	0
59	MON-LB102 Liquid L-Thyroxine Can Maintain Stable TSH Values in Patients with Hypothyroidism: A Prospective Study. Journal of the Endocrine Society, 2019, 3, .	0.2	0